277 related articles for article (PubMed ID: 21763939)
1. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
Karim SS; Kashuba AD; Werner L; Karim QA
Lancet; 2011 Jul; 378(9787):279-81. PubMed ID: 21763939
[No Abstract] [Full Text] [Related]
2. Antiretrovirals for HIV prevention: translating promise into praxis.
Mayer KH
Lancet; 2011 Jul; 378(9787):206-8. PubMed ID: 21763922
[No Abstract] [Full Text] [Related]
3. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
[TBL] [Abstract][Full Text] [Related]
4. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral prophylaxis: a defining moment in HIV control.
Karim SS; Karim QA
Lancet; 2011 Dec; 378(9809):e23-5. PubMed ID: 21771566
[No Abstract] [Full Text] [Related]
6. Antiretroviral vaginal gel shows promise against HIV.
Baleta A
Lancet; 2010 Jul; 376(9738):320. PubMed ID: 20681062
[No Abstract] [Full Text] [Related]
7. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
[TBL] [Abstract][Full Text] [Related]
8. FDA paves the way for pre-exposure HIV prophylaxis.
Holmes D
Lancet; 2012 Jul; 380(9839):325. PubMed ID: 22852138
[No Abstract] [Full Text] [Related]
9. Study halted: no benefit seen from antiretroviral pill in preventing HIV in women.
Stephenson J
JAMA; 2011 May; 305(19):1952. PubMed ID: 21586708
[No Abstract] [Full Text] [Related]
10. AIDS: Drugs that prevent HIV infection.
Wainberg MA
Nature; 2011 Jan; 469(7330):306-7. PubMed ID: 21248832
[No Abstract] [Full Text] [Related]
11. After CAPRISA 004: time to re-evaluate the HIV lexicon.
Cates W
Lancet; 2010 Aug; 376(9740):495-6. PubMed ID: 20709216
[No Abstract] [Full Text] [Related]
12. Preventing HIV in women--still trying to find their VOICE.
Saag MS
N Engl J Med; 2015 Feb; 372(6):564-6. PubMed ID: 25651251
[No Abstract] [Full Text] [Related]
13. [Pre-exposure prophylaxis for HIV transmission? No, unless].
Boeke AJ; Heijnen AM
Ned Tijdschr Geneeskd; 2013; 157(27):A6359. PubMed ID: 23838404
[TBL] [Abstract][Full Text] [Related]
14. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
Myers GM; Mayer KH
AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
[TBL] [Abstract][Full Text] [Related]
15. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.
Parikh UM; Dobard C; Sharma S; Cong ME; Jia H; Martin A; Pau CP; Hanson DL; Guenthner P; Smith J; Kersh E; Garcia-Lerma JG; Novembre FJ; Otten R; Folks T; Heneine W
J Virol; 2009 Oct; 83(20):10358-65. PubMed ID: 19656878
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
Jackson A; Moyle G; Watson V; Tjia J; Ammara A; Back D; Mohabeer M; Gazzard B; Boffito M
J Acquir Immune Defic Syndr; 2013 Mar; 62(3):275-81. PubMed ID: 23274933
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Okwundu CI; Uthman OA; Okoromah CA
Cochrane Database Syst Rev; 2012 Jul; (7):CD007189. PubMed ID: 22786505
[TBL] [Abstract][Full Text] [Related]
18. How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention.
Haire B; Kaldor J; Jordens CF
Am J Bioeth; 2012; 12(6):21-30. PubMed ID: 22650457
[TBL] [Abstract][Full Text] [Related]
19. The clinical pharmacology of antiretrovirals for HIV prevention.
Hendrix CW
Curr Opin HIV AIDS; 2012 Nov; 7(6):498-504. PubMed ID: 22964888
[TBL] [Abstract][Full Text] [Related]
20. The introduction of new antiretroviral-based HIV prevention methods into health systems: an update.
Daly F
Reprod Health Matters; 2012 Jun; 20(39):215. PubMed ID: 22789099
[No Abstract] [Full Text] [Related]
[Next] [New Search]
